Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 14, 2021
Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron...
-
Dec 14, 2021
Melbourne, 14 December 2021 – CSL Limited (ASX:CSL) and its vaccine business, Seqirus, today reaffirms a strong commitment to accelerating its proprietary next-generation self-amplifying mRNA...
-
Nov 30, 2021
Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies...
-
Nov 23, 2021
- CSL, WEHI and The University of Melbourne have secured funding to join forces and create an incubator and commercial wet lab space for biotech start-up companies - The project partners are...
-
Oct 27, 2021
Faster treatments for future pandemics (Brisbane) Investigating the DNA factory in our bodies that makes everything (Melbourne) MELBOURNE and BRISBANE; October 27, 2021: Two Australian scientists...
-
Oct 19, 2021
MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021: Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a...
-
Oct 14, 2021
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...
-
Oct 8, 2021
CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...
-
Sep 13, 2021
CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...
-
Jun 1, 2021
$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...
-
May 12, 2021
New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...
-
May 12, 2021
Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...
-
May 6, 2021
Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...
-
May 1, 2021
Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...
-
Apr 29, 2021
Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...
-
Apr 8, 2021
CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...
-
Apr 2, 2021
CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...
-
Apr 2, 2021
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...
-
Mar 24, 2021
Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of...
-
Feb 12, 2021
CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...
-
Jan 31, 2021
24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...
-
Nov 8, 2020
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...
-
Oct 15, 2020
Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health...
-
Oct 8, 2020
October 8, 2020, Melbourne — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the...
-
Oct 1, 2020
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...